<DOC>
	<DOCNO>NCT01363063</DOCNO>
	<brief_summary>This Phase 1 , double blind , two part study healthy male female volunteer . Each subject participate one part study . In Part A subject receive one dose 15 mg ketorolac tromethamine lidocaine hydrochloride free formulation one nostril one dose 15 mg ketorolac tromethamine contain 6 % lidocaine hydrochloride nostril , randomized manner . In Part B subject randomize receive single intranasal dose 15 mg ketorolac tromethamine contain 0 % lidocaine hydrochloride one nostril either placebo single intranasal dose 15 mg ketorolac tromethamine contain 0 % , 4 % 6 % lidocaine hydrochloride nostril . During study , subject remain resident morning Day 1 afternoon Day 1 , post-study medical perform prior discharge . The objective study compare tolerability formulation ketorolac tromethamine differ concentration lidocaine hydrochloride ( 0 % 6 % Part A 0 % , 4 % , 6 % placebo Part B ) follow intranasal administration healthy volunteer .</brief_summary>
	<brief_title>Study Tolerability Ketorolac Tromethamine Following Intranasal Administration Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<criteria>Male female volunteer , age 18 60 year inclusive Female subject child bear potential must negative urine pregnancy test prior entry study must breast feed All female subject child bear potential male subject female partner child bear potential must consent use medically acceptable method contraception ( oral implant contraceptive hormone , condom diaphragm spermicidal agent , intrauterine device surgical sterilization ) throughout study period Subject give sign informed consent Subject within 20 % normal weight his/her height body build accord table `` Desirable Weights Men Women '' ( Metropolitan Life Insurance Co. 1999 ) Subject 's medical history consider normal , clinically significant abnormality Subject consider good health opinion Investigator , determine prestudy physical examination clinically significant abnormality , vital sign within normal range electrocardiogram ( ECG ) clinically significant abnormality Subject 's prestudy clinical laboratory finding within normal range outside normal range deem clinically significant opinion Investigator Subject bilateral patent nasal airway screen Day 1 assess Investigator Body weight least 60 kg Subject clinically significant illness four week screen Use prescribe medication three week prior dose overthecounter preparation seven day prior dose , except paracetamol allow 48 hour prior dose . However , use multivitamins oral contraceptive permit Subject significant history drug/solvent abuse , positive drug abuse test screening Subject history alcohol abuse currently drink excess 28 unit per week ( male ) 21 unit per week ( female ) Current tobacco use history smoking within past five year Subject opinion Investigator suitable participate study Subject participate clinical study investigational drug/device within three month prior dose Subject positive result human immunodeficiency virus ( HIV ) screen , Hepatitis B screen Hepatitis C screen Subject serious adverse reaction significant hypersensitivity drug Subject donate 500 mL blood within three month prior screen Any history coexist nasal polyp , NSAID sensitivity asthma Allergic reaction aspirin NSAIDs Current upper respiratory tract infection respiratory tract condition could interfere absorption nasal spray assessment adverse event ( AEs ) Any suspicion rhinitis medicamentosa ( chronic daily use topical decongestant ) Use monoamine oxidase inhibitor 14 day prior study entry Active peptic ulcer disease , gastrointestinal bleeding perforation , history peptic ulcer disease gastrointestinal bleeding Anemia due unexplained known gastrointestinal bleeding History asthma chronic pulmonary disorder Renal impairment risk renal failure due volume depletion Known sensitivity lidocaine hydrochloride Previous history nasal surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>